Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium

Launched by SAMUEL LUNENFELD RESEARCH INSTITUTE, MOUNT SINAI HOSPITAL · Feb 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective different medications, known as uterotonics, are in helping the uterus contract after childbirth, especially when a medication called carbetocin has already been given. Strong uterine contractions are important to prevent heavy bleeding after delivery, a condition called postpartum hemorrhage. The researchers want to find out which of the other available uterotonics—oxytocin, ergometrine, or carboprost—works best if carbetocin alone isn’t enough to help the uterus contract properly.

To participate in the study, women must be between 18 and 45 years old, be scheduled for an elective cesarean section, and not be in labor or receiving certain medications that could affect uterine contractions. After the baby is born, a small piece of uterine tissue will be taken for testing in a lab. This research aims to improve treatments for reducing the risk of heavy bleeding after delivery, which is crucial for the health and safety of mothers. Participants will receive more information and guidance about what to expect during the study process.

Gender

FEMALE

Eligibility criteria

• • Inclusion criteria
• • Patients who give written consent to participate in this study
• • Patients with gestational age 37-41 weeks
• • Non-laboring patients, not exposed to exogenous oxytocin
• • Patients requiring elective primary or first repeat CD
• • Patients undergoing CD under spinal anesthesia
• • Exclusion criteria
• • Patient refusal
• • Patients who require general anesthesia
• • Patients in labour and those receiving oxytocin for induction of labour
• • Emergency CD
• • placenta accreta spectrum disorder
• • Patients who have had previous uterine surgery or \>1 previous CD
• • Patients with any condition predisposing to uterine atony and PPH (BMI \> 40 kg/m2,
• • Patients on medications that could affect myometrial contractility, such as insulin, nifedipine, labetalol or magnesium sulphate.